^
Association details:
Biomarker:No biomarker
Cancer:Diffuse Large B Cell Lymphoma
Regimen: (mesna + etoposide IV + mitoxantrone + ifosfamide)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Published date:
01/20/2021
Excerpt:
Diffuse large B-Cell Lymphoma: SECOND-LINE AND SUBSEQUENT THERAPY…Other recommended regimens…MINE (mesna, ifosfamide, mitoxantrone, etoposide) ± rituximab